<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125630</url>
  </required_header>
  <id_info>
    <org_study_id>BOMET MF14-01</org_study_id>
    <secondary_id>PROTOCOL BOMET MF14-01</secondary_id>
    <nct_id>NCT02125630</nct_id>
  </id_info>
  <brief_title>Bone Metastasis in Breast Cancer</brief_title>
  <official_title>The Effect of Primary Surgery in Patients With Stage IV Breast Cancer With Bone Metastasis Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation of Breast Diseases Societies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation of Breast Diseases Societies</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized trial evaluating resection of the primary breast tumor in women presenting with
      de novo stage IV breast cancer with bone metastasis only. Previous reports of carefully
      selected patients presenting with stage IV breast cancer suggest that surgery on the primary
      tumor may result in improved survival, but this remains unproven. The early results of our
      ongoing trial MF07-01 trial (a phase III randomized controlled trial of breast cancer women
      with distant metastases at presentation who receive loco-regional treatment for intact
      primary tumor compared with those who do not receive such treatment) showed that patients
      with bone metastasis only have a trend toward improved survival with initial surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Metastatic Breast Carcinoma With Bone Metastasis Only</condition>
  <condition>Primary Surgery</condition>
  <arm_group>
    <arm_group_label>Systemic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standart chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standart surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>Primary surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic therapy</intervention_name>
    <arm_group_label>Systemic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary breast tumor amenable for complete surgical resection

          -  Patients in good physical condition for receiving protocol driven locoregional and
             systemic treatment

          -  Patients eligible for sentinel lymph node (SLN) biopsy and receiving radiotherapy.

        Exclusion Criteria:

          -  Primary tumor not amenable for complete resection (such as tumor extending to
             neighboring tissues; T4a,c or inflammatory breast cancer; T4d)

          -  Primary tumor with extended infection, bleeding, or necrosis

          -  Patients with poor physical condition which prevents the patient from receiving
             protocol driven locoregional and systemic treatment

          -  Synchronous primary cancer at the contralateral breast

          -  Previous diagnosis of other cancers (excluding basal cell skin cancer

          -  Squamous cell skin cancer

          -  Cervical intraepithelial neoplasia)

          -  Clinically involved contralateral axillary nodes

          -  Patients not suitable for adequate follow-up

          -  Failure to give informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atilla Soran, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Magee-Womens Hospital of UPMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serdar Ozbas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guven Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul University Medical faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vahit Ozmen, MD</last_name>
      <phone>905322150777</phone>
      <email>vozmen@istanbul.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Abdullah Igci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahmut Muslumanoglu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast carcinoma</keyword>
  <keyword>Bone metastasis</keyword>
  <keyword>Primary surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
